Who Generates More Revenue? AbbVie Inc. or Bristol-Myers Squibb Company

AbbVie vs. Bristol-Myers: A Decade of Revenue Rivalry

__timestampAbbVie Inc.Bristol-Myers Squibb Company
Wednesday, January 1, 20141996000000015879000000
Thursday, January 1, 20152285900000016560000000
Friday, January 1, 20162563800000019427000000
Sunday, January 1, 20172821600000020776000000
Monday, January 1, 20183275300000022561000000
Tuesday, January 1, 20193326600000026145000000
Wednesday, January 1, 20204580400000042518000000
Friday, January 1, 20215619700000046385000000
Saturday, January 1, 20225805400000046159000000
Sunday, January 1, 20235431800000045006000000
Monday, January 1, 20245633400000048300000000
Loading chart...

Unleashing insights

Revenue Race: AbbVie Inc. vs. Bristol-Myers Squibb Company

In the competitive landscape of the pharmaceutical industry, revenue generation is a key indicator of a company's market strength and innovation prowess. From 2014 to 2023, AbbVie Inc. and Bristol-Myers Squibb Company have been at the forefront, showcasing impressive financial growth. AbbVie Inc. has consistently outperformed its rival, with a remarkable 172% increase in revenue over the decade, peaking in 2022. In contrast, Bristol-Myers Squibb Company saw a 184% rise in revenue, with its highest earnings in 2021. Notably, AbbVie's revenue surged past Bristol-Myers in 2020, maintaining a lead with a 20% higher revenue in 2023. This trend highlights AbbVie's strategic advancements and market adaptability. As these giants continue to innovate, investors and stakeholders keenly watch their financial trajectories, anticipating future shifts in this dynamic revenue race.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025